AMPLIA THERAPEUTICS LIMITED revenue for the last year amounted to 100.00 M AUD, the most of which — 15.00 k AUD — came from its highest performing source at the moment, Focal Adhesion Kinase, the year earlier bringing 41.05 k AUD. The greatest contribution to the revenue figure was made by Australia — last year it brought AMPLIA THERAPEUTICS LIMITED 15.00 k AUD, and the year before that — 41.05 k AUD.